Central obesity is associated with increased morbidity and mortality. Preadipocyte proliferation and differentiation contribute to increases in adipose tissue mass, yet the mechanisms that underlie these processes remain unclear. Patients with glucocorticoid excess develop a reversible form of central obesity, but circulating cortisol levels in idiopathic obesity are invariably normal. We have hypothesized that the enzyme 11␤-hydroxysteroid dehydrogenase type 1 (11␤-HSD1), by converting inactive cortisone to active cortisol in adipose tissue, might be an important autocrine regulator of fat mass.
T HE GLOBAL EPIDEMIC of obesity (1) has focused attention on the mechanisms that underlie its pathogenesis. As the incidence of obesity continues to escalate, so do its major complications, namely type 2 diabetes, hypertension, and ischemic heart disease. Although obesity per se is clearly linked to excess morbidity and mortality (1, 2) , fat distribution is highly relevant. Central or visceral adiposity carries a more severe adverse metabolic profile and increased morbidity than peripheral adiposity (3) , highlighting the need to identify factors regulating fat distribution.
Patients with glucocorticoid excess, Cushing's syndrome, develop florid, but reversible, central obesity. However, circulating cortisol (F) levels in simple obesity are normal or slightly reduced compared with those in lean controls (4) . Two isoforms of the enzyme 11␤-hydroxysteroid dehydrogenase (11␤-HSD) play a crucial role in the prereceptor metabolism of F (5). Type 1 (11␤-HSD1) is widely expressed in many tissues, including liver, adipose tissue, gonad, and bone (6, 7) , where it activates F from cortisone (E). 11␤-HSD1 is a bidirectional enzyme, and although in vivo the reductase activity predominates, in tissue homogenates only dehydrogenase activity is observed. The underlying mechanism remains unclear, but cofactor availability may be crucial (7a) . The type 2 isozyme (11␤-HSD2) is a high affinity dehydrogenase inactivating F to E, located principally in mineralocorticoid target tissues, including kidney and placenta. It serves to protect the mineralocorticoid receptor from illicit occupation by F (for which it has the same affinity as aldosterone). Defects in this enzyme explain the rare, life-threatening form of hypertension and hypokalemia, apparent mineralocorticoid excess (8) , and also explain the hypertension induced by liquorice (9) . 11␤-HSD2 is not expressed in human adipose tissue (10) .
The role of 11␤-HSD1 in adipose tissue has been investigated. Within isolated preadipocytes we have previously demonstrated enhanced activity in omental (om) compared with sc cells (10) together with further induction of activity by F itself. At this site, the enzyme appears to facilitate adipocyte differentiation (11) , and this is supported by the recent report of transgenic mice overexpressing 11␤-HSD1 within adipocytes (12) . Therefore, it has been postulated that central obesity reflects local F excess specifically within adipose tissue (10, 11, 13) . However, clinical studies suggest inhibition of 11␤-HSD1, at least in the liver, in obese subjects (14, 15) . The concept has therefore evolved that the centrally obese phenotype results as a consequence of differential regulation of 11␤-HSD1 inhibition within the liver and upregulation within adipose tissue.
To date, there are only limited data on the expression of 11␤-HSD1 in adipose tissue in human obesity and no data at all on om 11␤-HSD1 expression as a function of the body mass index (BMI). We have therefore determined the depotspecific activity and expression of 11␤-HSD1 in whole adipose tissue and in isolated adipocytes and preadipocytes in human obesity.
The roles of F and 11␤-HSD1 in adipocyte differentiation are well established (11, 12) . However, increases in adipose tissue mass arise as a result of adipocyte differentiation and lipid accumulation as well as preadipocyte proliferation and recruitment. However, glucocorticoids generally inhibit cellular proliferation (16, 17) , and in recent studies we have demonstrated the impact of 11␤-HSD-mediated F/E metabolism on cell proliferation in transfected cell lines (18) . Overexpression of 11␤-HSD2 enhanced proliferation, but overexpression of 11␤-HSD1 had the opposite effect. In addition, we have investigated the role of 11␤-HSD1 in om preadipocyte proliferation.
Subjects and Methods
The study had the approval of the local research ethics committee. Thirty-two consecutive women (median age, 43 yr; range, 28 -65; median BMI, 27.5 kg/m 2 ; range, 19.7-39.2) undergoing elective abdominal surgery were recruited for the study, and all gave written consent. Patients with diabetes mellitus and those who had received glucocorticoid therapy within the last 12 months were excluded from the study. The clinical characteristics of the patients, divided into obese and nonobese by BMI according to WHO criteria (19), are presented in Table 1 . Importantly, because of the well described actions of cytokines on the activity and expression of 11␤-HSD1 (20) , all operations were for noninflammatory and nonmalignant conditions. Paired sc and om fat biopsies were obtained from each patient. Samples were processed within 30 min of removal from the patient. Each sample was divided; one part was snap-frozen in liquid nitrogen and stored at -70 C for total RNA extraction at a later date, and the remainder was used for adipocyte isolation and preadipocyte culture when sufficient tissue was available (n ϭ 20). Subgroup analysis of the clinical characteristics of this cohort was not different from that of the whole cohort.
Isolation of adipocytes and primary cultures of human preadipocytes
Adipocytes and preadipocytes were isolated as previously reported (10, 21) . Briefly, om or sc adipose tissue was washed in PBS containing 50,000 U penicillin and 50,000 g streptomycin (Life Technologies, Inc., Paisley, UK). The tissue was then prepared and digested with collagenase class 1 (2 mg/ml; Worthington Biochemical Corp., Reading, UK) in 1ϫ Hanks' balanced salt solution (Life Technologies, Inc.) for 45 min at 37 C. Samples were centrifuged at 90 ϫ g for 1 min, the intact adipocyte layer was removed, and RNA was extracted as described below. Samples were then centrifuged at 90 ϫ g for 5 min, the pellet containing preadipocytes was removed, and cells were washed with DMEM/Nutrient Mixture F-12 (Life Technologies, Inc.) containing 15% fetal calf serum (Life Technologies, Inc.) and seeded on 12-well plates (Costar, Cambridge, MA). Cells were left overnight, washed the following day with 1ϫ Hanks' balanced salt solution, and then cultured to confluence in DMEM/Ham's F-12 medium containing 15% fetal calf serum with or without 100 nm F (Sigma, Poole, UK).
11␤-HSD assay
Assays for 11␤-HSD1 activity were performed by incubating intact cells with 100 nm E and tritiated tracer for 16 h to ensure first order kinetics. After incubation, steroids were extracted using dichloromethane, separated using a mobile phase consisting of ethanol and chloroform (8:92) by thin layer chromatography, and scanned using a Bioscan 3000 image analyzer (Lablogic, Sheffield, UK). Protein levels were assayed using a commercially available kit (Bio-Rad Laboratories, Inc., Hercules, CA), and activity was expressed as picomoles of product per milligrams of protein per hour. All experiments were carried out in triplicate.
RNA extraction and RT
Total RNA was extracted using a single step extraction method [TriReagent, Sigma (preadipocytes and adipocytes), or Genelute total mammalian RNA extraction kit, Sigma (adipose tissue)]. RNA integrity was assessed by electrophoresis on 1% agarose gels, and quantity was determined spectrophotometrically at OD 260 . One microgram of total RNA was initially denatured by heating to 70 C for 5 min. Thirty units of avian myeloblastosis virus, 200 ng random primers, 20 U ribonuclease inhibitor, and 40 nmol deoxy-NTPs with 5ϫ reaction buffer were added to the RNA, and the reverse transcriptase reaction was carried out at 37 C for 1 h. The reaction was terminated by heating the cDNA to 95 C for 5 min.
Real-time PCR
11␤-HSD1 mRNA levels were analyzed using an ABI 7700 sequence detection system (Perkin-Elmer, Warrington, UK) that employs TaqMan chemistry for highly accurate quantification of mRNA levels as previously described (22) . Real-time PCR was performed in 25-l volumes on 96-well plates in reaction buffer containing TaqMan Universal PCR Master Mix, 3 mm Mn(Oac) 2 , 200 m deoxy-NTPs, 1.25 U AmpliTaq Gold polymerase, 1.25 U AmpErase UNG (Perkin-Elmer, Warrington, UK), 100 -200 nmol TaqMan probe, 900 nmol primers, and 25-50 ng cDNA. All reactions were multiplexed with the housekeeping gene (18S), provided as a preoptimized control probe (Perkin-Elmer), enabling data to be expressed in relation to an internal reference to allow for differences in RT efficiency. Data were obtained as ct values according to the manufacturer's guidelines (the cycle number at which logarithmic PCR plots cross a calculated threshold line) and were used to determine ⌬ct values (⌬ct ϭ ct of the target gene minus ct of the housekeeping gene). Fold changes in expression were calculated according to the transformation: fold increase ϭ 2 Ϫ difference in ⌬ct . All target gene probes were labeled with the fluorescent label FAM, and the housekeeping gene was labeled with the fluorescent label VIC. Reactions were as follows: 50 C for 2 min, 95 C for 10 min, and then 44 cycles of 95 C for 15 sec and 60 C for 1 min.
To exclude potential bias owing to averaging data that had been transformed through the equation 2
Ϫct , all statistics were performed at the ct stage. Statistical analysis of comparisons among groups was undertaken using paired and unpaired t tests where appropriate.
Oligonucleotide primers and a TaqMan probe for 11␤-HSD1 were as follows: forward, AGGAAAGCTCATGGGAGGACTAG; reverse, AT-GGTGAATATCATCATGAAAAAGATTC; and probe, CATGCTCAT-TCTCAACCACATCACCAACA.
Preadipocyte proliferation
In a subset of the patients described above (n ϭ 7; median BMI, 30.1 kg/m 2 ; range, 22.9 -33.5; median age, 45 yr; range, 30 -65), preadipocyte proliferation was assessed using tritiated thymidine incorporation as described previously (18) . Preadipocytes were cultured and incubated with either 1 m E, 100 nm F, and 5 m 18␤-glycyrrhetininc acid (GE; 16 h. Cells were then washed twice in PBS and once in 1 ml cold 5% trichloroacetic acid to precipitate proteins, then were left on ice for 20 min. The liquid layer was removed and drained. An aliquot (250 l) of 0.1 m sodium hydroxide was added to the cells and left at room temperature for 30 min on a shaker. The resulting solubilized nuclear material was then transferred to 4 ml scintillant, and radioactive counts were determined by liquid scintillation counting.
Statistical analysis
Data are expressed as the mean Ϯ se unless otherwise stated. Initial linear regression analysis was performed using Pearson's correlation coefficient. Subsequent analysis used unpaired t test to compare obese and nonobese groups and single treatments to controls. Paired t tests were used to compare matched samples from the same subject. Where multiple treatments are compared, one-way ANOVA of ranks was used. Statistical analysis of real-time PCR data was performed on mean ⌬ct values and not fold changes.
Results

Obese vs. nonobese
In whole adipose tissue, 11␤-HSD1 mRNA levels did not correlate with body mass index (om: r ϭ 0.1; P ϭ 0.6; sc: r ϭ 0.15; P ϭ 0.4). When divided into obese and nonobese groups, there was no significant difference in mRNA levels in whole tissue or adipocytes in either sc or om depots (Table 2) .
11␤-HSD1 activity in om preadipocytes inversely correlated with BMI (r ϭ Ϫ0.47; P ϭ 0.03; Fig. 1 ). Furthermore, when divided by BMI, 11␤-HSD1 activity in om preadipocytes cultured with F was lower in obese patients (P ϭ 0.04, obese vs. nonobese; Fig. 2A ). In sc samples cultured with F, there was no difference in activity between obese and nonobese patients. Cells cultured without F demonstrated the same pattern, although results failed to reach statistical significance (Table 2) .
Regulation appeared to be at a transcriptional level; 11␤-HSD1 mRNA levels were 1.9-fold higher in om preadipocytes from nonobese subjects than in those from obese subjects. Levels of 11␤-HSD1 mRNA were similar in sc preadipocytes from obese and nonobese subjects (Table 2 and Fig. 2B ).
Omental vs. sc depots
In whole adipose tissue 11␤-HSD1 mRNA levels did not differ between om and sc samples (P ϭ 0.73). As previously reported by our group, 11␤-HSD1 activity was significantly higher in cultured om than in sc preadipocytes (P ϭ 0.002). F induced activity in both sc and om preadipocytes (Table 2) . Differences in enzyme activity between om and sc depots were reflected in levels of 11␤-HSD1 mRNA. Using real-time PCR, 11␤-HSD1 mRNA levels were 4.8-fold higher in om compared with sc preadipocytes cultured with F (Table 2) .
Adipocytes vs. preadipocytes
In the om depot, 11␤-HSD1 mRNA levels were higher in preadipocytes than in adipocytes (P ϭ 0.04), whereas in the sc depot, mRNA levels were similar in both cell types (P ϭ 0.62; Table 2 and Fig. 3 ).
Omental preadipocyte proliferation
In om preadipocytes, both F and E decreased proliferation [F, 35.6 Ϯ 3.6%; E, 59.3 Ϯ 4.4%; P Ͻ 0.05, vs. control (100%)]. Inhibition of 11␤-HSD1 with GE partially reversed the Einduced decrease in om preadipocyte proliferation (E, 59.3 Ϯ 4.4%; E plus GE, 76.8 Ϯ 4.6%; P Ͻ 0.05; Fig. 4 ).
Discussion
We have characterized the expression of 11␤-HSD1 in adipose tissue in human obesity. Within adipose tissue and isolated adipocytes, 11␤-HSD1 mRNA levels did not differ between sc and om depots and did not correlate with BMI. There were, however, decreased 11␤-HSD1 mRNA levels and activity within the om preadipocyte pool of obese patients. Furthermore, inhibition of 11␤-HSD1 within om preadipocytes partially relieved the E-induced inhibition of preadipocyte proliferation.
Patients with glucocorticoid excess, Cushing's syndrome, develop florid, but reversible, central obesity, but in simple obesity, circulating F levels are normal or slightly reduced (4). However, the metabolic clearance rate of F is increased in obesity, and as a consequence, there is increased F secretion driven by ACTH (4, 23, 24) . Global inhibition of 11␤-HSD1 in obesity (14, 15) with impaired E to F conversion probably accounts for the observed enhanced metabolic clearance rate of F.
At a prereceptor level, we have previously shown 11␤-HSD1 expression to be higher in om compared with sc preadipocytes (10), an observation that was endorsed by this study. This has lead to the speculation that 11␤-HSD1 may have a crucial role to play in the pathogenesis of central obesity. Accumulation of adipose tissue mass may occur in several ways: adipocyte differentiation, increased lipid accumulation within already differentiated cells, and preadipocyte proliferation, increasing the pool of cells available to undergo differentiation. F is an essential requirement for adipocyte differentiation (25) , and 11␤-HSD1 has been shown to be an important modulator of this process. Thus, inhibition of 11␤-HSD1 prevented E-induced adipocyte differentiation in om preadipocytes (11) . Transgenic mice over-FIG. 2. 11␤-HSD1 activity in isolated cultured sc and om preadipocytes from obese and nonobese women. Cells were cultured with and without 100 nM F. Activity is significantly higher in om preadipocytes from nonobese patients (A). Regulation of enzyme activity is at the transcriptional level. mRNA levels are 4.9-fold higher in om compared with sc preadipocytes and higher in om preadipocytes from nonobese patients, mirroring activity data (B). expressing 11␤-HSD1 under the aP2 promoter develop an obese phenotype as a consequence of elevated adipose tissue corticosteroid concentrations (12) . In this model, because the transgene was directed to the adipocyte-specific aP2 promoter, increases in adipose tissue mass were solely a consequence of increased lipid accumulation within preexisting adipocytes.
A fundamental action of glucocorticoids is to inhibit cellular proliferation by inducing cell cycle arrest at the G 1 phase (17, 26) . Prereceptor modulation of F metabolism has been shown to have a dramatic effect on the cell proliferation rate (18) . Overexpression of 11␤-HSD2 enhances proliferation, whereas 11␤-HSD1 inhibits proliferation, an effect that relies on the paracrine/autocrine inactivation (11␤-HSD2) or generation (11␤-HSD1) of F within the cell system. In rat preadipocytes glucocorticoids exert an antiproliferative effect (16) . Similarly, we have now demonstrated inhibition of human om preadipocyte proliferation with F. This effect was also modulated by 11␤-HSD1; inhibition of 11␤-HSD1 activity with GE limited the antiproliferative effect of E. The prereceptor hormone metabolism of F therefore has an important impact not only on adipocyte differentiation, but also on preadipocyte proliferation. In whole adipose tissue, 11␤-HSD1 would act to increase adipocyte differentiation, but simultaneously inhibit preadipocyte proliferation, and the overall impact of this upon adipose tissue mass needs to be considered.
Interestingly, in this context the 11␤-HSD1 knockout mouse does not appear to have an obvious adipose tissue phenotype (27) . Histological data are not available, but we would speculate that enhanced fat cell number will occur at the expense of fat cell size, the exact converse of the aP2 11␤-HSD1-overexpressing mouse. The human correlate of this model is a patient with the putative 11␤-HSD1-deficient state, the syndrome of apparent cortisone reductase deficiency (28 -33) . Although there have been no detailed studies of fat distribution in these patients, these patients are not invariably lean (28, 29) . Enhanced preadipocyte proliferation within the om depot in these patients may offset any potential benefits on adipocyte differentiation and predispose them to central fat accumulation.
Although we (14) and others (15) have reported reduced hepatic expression of 11␤-HSD1 in obese subjects, it has been hypothesized from rodent studies that increased 11␤-HSD1 expression within adipose tissue might explain an obese phenotype (13, 15) . However, within this area there are pitfalls in extrapolating from rodents to humans. Efforts have been made to examine 11␤-HSD1 activity in sc adipose tissue of obese patients (15, 34) , but only inappropriate dehydrogenase assays on tissue homogenates have been performed (15) . Furthermore, sc and om depots are not identical, as this study highlights, there are marked depot-specific differences in the expression of 11␤-HSD1, and the propensity for proliferation and differentiation is well documented (10, 35, 36) .
In this study there was no evidence for overexpression of 11␤-HSD1 in obesity in whole adipose tissue, adipocytes, or preadipocytes; indeed, 11␤-HSD1 activity and mRNA levels were decreased in preadipocytes from obese patients. These data therefore indicate that increased expression of 11␤-HSD1 within om adipose tissue is not a primary cause of obesity. Unfortunately, although we had access to om adipose tissue biopsies, comparisons were only possible with BMI. A detailed assessment of 11␤-HSD1 expression in the context of rigorous adipose tissue distribution is now warranted.
These data add a new layer of complexity to the role of prereceptor F metabolism in the pathogenesis of central obesity. 11␤-HSD1 expression within adipose tissue regulates both adipocyte differentiation and preadipocyte proliferation. Although central obesity may not simply be "Cushing's disease of the omentum," reflecting increased expression of 11␤-HSD1, the challenge for the future will be to determine the relative contributions of 11␤-HSD1 to differentiation and proliferation in the regulation of adipose tissue mass.
